SCHEMBL19946157

SCHEMBL19946157

Cc1c(Br)ncc2c1c1ccc(Cl)cc1c(=O)n2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 6/20 0.39
GABRG2 P18507 6/20 0.39
GABRB3 P28472 6/20 0.39
GABRA5 P31644 6/20 0.39
MAPK8 P45983 3/20 0.38
MAPK9 P45984 3/20 0.38
MAPK10 P53779 2/20 0.36
AAK1 Q2M2I8 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MAT2A P31153 1/20 0.36
DPP4 P27487 1/20 0.35
KMT2A Q03164 1/20 0.34
PLK4 O00444 1/20 0.34
AURKA O14965 1/20 0.34
RPS6KA4 O75676 1/20 0.34
MAPKAPK2 P49137 1/20 0.34
GSK3B P49841 1/20 0.34
MARK2 Q7KZI7 1/20 0.34
BRSK1 Q8TDC3 1/20 0.34
AURKB Q96GD4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19946166 0.77 GABRA1 (0.41) GABRA1GABRG2GABRB3GABRA5AAK1
SCHEMBL19946180 0.76 AAK1 (0.52) GABRA1GABRG2GABRB3GABRA5MAPK8
SCHEMBL21978885 0.69 MAT2A (0.46) RXFP1MAT2AGSK3B
SCHEMBL21978677 0.69 RAB9A (0.41) GABRA1GABRG2GABRB3GABRA5MAPK8
SCHEMBL30901317 0.69 MAT2A (0.46) RXFP1MAT2AGSK3B
SCHEMBL19946155 0.69 ROCK2 (0.58) GABRA1GABRG2GABRB3GABRA5AAK1
SCHEMBL15455077 0.68 MAT2A (0.45) GABRA1GABRG2GABRB3GABRA5AAK1
SCHEMBL15454732 0.67 MAT2A (0.46) GABRA1GABRG2GABRB3GABRA5MAPK8
SCHEMBL23442969 0.65 KDM4E (0.42) GABRA1GABRG2GABRB3GABRA5MAPK8
SCHEMBL19946154 0.65 AAK1 (0.52) GABRA1GABRG2GABRB3GABRA5AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3292124-B1 6H-ISOCHROMENO[3,4-C]PYRIDINES AND BENZO[C][1,7]NAPHTHYRIDIN-6-(5H)-ONES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-05-22 EP disclosed
US-10174044-B2 Fused pyridines as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2019-01-08 US disclosed
US-20180141956-A1 FUSED PYRIDINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-05-24 US disclosed
EP-3292124-A2 FUSED PYRIDINES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS Bristol-Myers Squibb Company (US) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10174044-B2 Fused pyridines as kinase inhibitors AAK1, NCK1, ADCK1 GABRA1 2722/4885GABRG2 2800/4885GABRB3 2512/4885
US-20180141956-A1 FUSED PYRIDINES AS KINASE INHIBITORS AAK1, NCK1, ADCK1 GABRA1 2722/4885GABRG2 2800/4885GABRB3 2512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.